This profile was last updated on .
Is this you? Claim your profile.
Fox Chase Cancer Center
333 Cottman Avenue
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among...
Find other employees at this company (1,667)
(32 Total References)
Liz Tilberis Early Career Award - OCRF Grantees | Ovarian Cancer Research Fund
2006 & 2003 Liz Tilberis Grant Recipient - Denise C. Connolly
Denise C. Connolly, Ph.D. - Fox Chase Cancer Center (Renewal)
Denise C. Connolly, Ph.D. - Fox Chase Cancer Center
Fox Chase Cancer Center : Fox Chase Research Faculty - Alphabetical Listing
Denise C. Connolly, PhD
Leadership Delaware - Speakers
Funding agency: NSF. ? _"Detection and diagnosis of early ovarian cancer using novel sensitive optical techniques" in collaboration with Denise Connolly, Fox Chase Cancer Center.
March 2006- March 2009.
Funding agency: DOD. ? _"Pulsed thermal lens laser spectroscopy of atmospheric species" Submitted to NASA, Delaware Space Program.
Professional Affiliations: ? _Member, American Physical Society ? _Member, Optical Society of America ? _Member, Emerging Technology Council, State of Delaware ? _Board Member, Delaware Authority on Radiation Safety
That's what really causes mortality," ...
That's what really causes mortality," says Denise C. Connolly, PhD, Associate Professor at Fox Chase and senior researcher for the project.
Research done by Fang Xiao, MD, ...
Research done by Fang Xiao, MD, PhD, Research Associate at Fox Chase, and Denise Connolly, PhD, Associate Professor at Fox Chase, led them to identify the importance of FAK in ovarian cancer, but the enzyme wasn't part of their investigation at the beginning.
But STAT3 itself is not a promising candidate for targeted therapy, Connolly
says, because, as a transcription factor, it lacks catalytic activity that could be blocked directly.
Suspecting they could find a related molecule to inhibit the protein's actions in cancer cell lines, Xiao and Connolly
conducted laboratory experiments to better understand the underlying biology.
"What's unique about Xiao's study is that focal adhesion kinase so far hasn't been shown to activate STAT3 in solid tumors," says Connolly
, whose research focuses on understanding the biological underpinnings of epithelial ovarian cancer.